From f64c0278339f9d2662be243be1288d043deb3298 Mon Sep 17 00:00:00 2001 From: Borja Robert Date: Mon, 19 Feb 2024 16:10:36 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/STOP2030___Web.md | 6 +++--- 1 file changed, 3 insertions(+), 3 deletions(-) diff --git a/pages/STOP2030___Web.md b/pages/STOP2030___Web.md index ab8271fe..3cb24192 100644 --- a/pages/STOP2030___Web.md +++ b/pages/STOP2030___Web.md @@ -38,15 +38,15 @@ - No stopping rules were reached - Safety was adequate - Palatability results confirm adecuacy of size, taste and smell - - Superior efficacy against T. trichiura confirm + - Superior efficacy against T. trichiura confirms a comprehensive spectrum against STH - ## Otros facts - FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016) - - Investigadores principales de cada uno de los partners - - Ideas generales importantes - Dosing strategies for Ivermectine are being revisited - The fix-dose coformulation of Albendazole/Ivermectine is due to enter regulatory agencies - Acceptability and safety studies are underway - The access plan is being developed + - Investigadores principales de cada uno de los partners + - Ideas generales importantes - Integration across programs (these results have implications beyond STH) - Progress has been achieved through public-private partnerships but more partners are needed to reach the ultimate goal. - El abstract del proyecto?